Tenon Medical, Inc. (NASDAQ: TNONW)

Tenon Medical, Inc., also known as TNON, is a company operating in the medical device industry. It is headquartered in Los Gatos, California, and was incorporated in Delaware in 2012. The company's primary business activity is the design, development, and commercialization of medical devices for the treatment of sacroiliac joint (SI Joint) disorders.

Tenon Medical has developed the Catamaran SI Joint Fusion System, a novel, less invasive approach to SI Joint disorders. The Catamaran System is a single, robust, titanium implant designed to provide a less invasive approach to SI Joint fusion. The system features a patented dual pontoon open cell design, which enables the clinician to pack the pontoons with the patient's own autologous bone to promote bone fusion across the joint. The system is designed to resist vertical shear and rotation of the joint, providing a secure press fit of the implant and reducing the incidence of revision surgery due to implant loosening.

The company believes that the Catamaran System offers several advantages over existing competitive devices, including a safer and faster surgical procedure, reduced post-operative pain, and a lower risk of complications. The system is designed to be used in a minimally invasive approach, which reduces the risk of complications and promotes faster recovery times.

Tenon Medical's primary customers are orthopedic surgeons and pain management specialists who treat patients with SI Joint disorders. The company markets and sells its products primarily through independent distributors and sales representatives specializing in spine sales. The company's competitive landscape is characterized by several established players in the spine and orthopedic device market. However, Tenon Medical believes that its unique approach and technology differentiate it from its competitors and provide a significant advantage in the market.

The company estimates that the potential market for surgical intervention of the SI Joint is approximately 279,000 procedures annually in the United States alone, representing a potential annual market of approximately $2.0 billion. Tenon Medical believes that its unique approach and technology will allow it to capture a significant share of this market.

In terms of regulatory status, Tenon Medical has received FDA 510(k) clearance to market and sell the Catamaran System for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The company's products are subject to FDA regulation, and it is required to comply with FDA regulations, including those related to product design, development, and manufacturing, labeling, and marketing.

Tenon Medical is committed to ongoing innovation and improvement of its products and technologies. The company is currently developing new advancements in and around the SI Joint and pelvic region, and is executing post-market clinical research to confirm the benefits of its distinct approach and implant.

The Catamaran SI Joint Fusion System is Tenon Medical's primary product. The system is designed to be used in a minimally invasive approach, which reduces the risk of complications and promotes faster recovery times. The company's customers are orthopedic surgeons and pain management specialists who treat patients with SI Joint disorders.